BD
BDTX.O
—
NASDAQ
Pharmaceuticals & Medical Research
Black Diamond Therapeutics Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
97,4M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
17,9 %
ROE
19,9 %
Net margin
32,0 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
376
Day range
—
Prev close
$2,33
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Black Diamond Therapeutics Inc is a biotechnology company focused on the discovery and development of novel therapeutics, primarily in the field of oncology and autoimmune diseases.
Business. Black Diamond Therapeutics Inc (BDTX.O) is a biotechnology company operating within the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY9 analysts
8 buy1 hold0 sell
Avg 12m price target9,86
Analyst recommendations
9 analysts · consensus BuyBuy8
Hold1
Sell0
12-month price target
9,86
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
9 analysts · indicative
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
19,9 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to BDTX.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Black Diamond Therapeutics Inc (BDTX.O) is a biotechnology company operating within the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATEDBlack Diamond Therapeutics maintains a strong liquidity position, with a current ratio of 8.42 and $20.99 million in cash and equivalents, indicating a robust ability to meet short-term obligations. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage risk. The liquidity FPT (free cash flow to total liabilities) is 0.736, further reinforcing the company's strong liquidity profile.
The company's profitability is notable, with a net income of $22.37 million and an operating income of $12.52 million, translating to a return on equity (ROE) of 19.93% and a return on assets (ROA) of 15.64%. These metrics exceed the typical performance of the biotechnology industry, where ROE and ROA are often lower due to high R&D costs and long development cycles.
Black Diamond Therapeutics does not disclose segment or geographic revenue breakdowns in the latest financial data, making it difficult to assess revenue concentration or geographic exposure. However, the company's operations are primarily based in the United States, and its pipeline is focused on global therapeutic markets, suggesting a broad geographic reach.
The company's growth trajectory is positive, with a revenue of $70 million and a net income of $22.37 million in the latest period. Analysts have set a mean price target of $9.86, with a median of $10.00, indicating strong confidence in the company's future performance. The mean recommendation of 1.78 (on a scale from 1 to 5) further supports a positive outlook.
The risk assessment for Black Diamond Therapeutics is favorable, with low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and its capital structure is free of long-term debt. The dilution potential is low, and no significant dilution sources were identified in the latest filings.
Recent events and filings indicate a stable and growing company. The company has a strong cash position and is generating positive free cash flow, which supports its ongoing R&D activities and potential future growth. Analysts have provided a range of price targets from $7.00 to $14.00, with a strong buy recommendation from three analysts and a buy recommendation from five analysts.
Key takeaways
- Black Diamond Therapeutics has a strong liquidity position with $20.99 million in cash and a current ratio of 8.42.
- The company's profitability is robust, with a return on equity of 19.93% and a return on assets of 15.64%.
- Analysts have set a mean price target of $9.86, with a median of $10.00, indicating strong confidence in the company's future performance.
- The company has no long-term debt and a low risk of dilution, making it a relatively safe investment in the biotechnology sector.
- Black Diamond Therapeutics is generating positive free cash flow, which supports its ongoing R&D activities and potential future growth.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$1,70
Market cap
$155.6M
Enterprise valueⓘ
$134.6M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
4.5x
P / Bⓘ
1.4x
P / Tangible bookⓘ
1.4x
Tangible book
$112.2M
Net cashⓘ
$21.0M
Current ratioⓘ
8.4
Debt / equityⓘ
0.0
ROAⓘ
15.6%
ROEⓘ
19.9%
Cash conversionⓘ
132.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
Partners1
Guardant Health IncGH.OPartner95%Source ↗
Supply chain
Vendors → BDTX ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison8 peers · vs BDTX · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
+12,6 vs self
Div yield
—
— vs self
ROE
40,4 %
+20,5 vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
-67,8 vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
-180,1 vs self
VC
VCYT—
Veracyte Inc
$45,30
3,6B USDP/E
55,5x
+48,6 vs self
Div yield
—
— vs self
ROE
5,1 %
-14,9 vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
+4,1 vs self
Div yield
—
— vs self
ROE
18,9 %
-1,0 vs self
AV
AVIR—
Atea Pharmaceuticals Inc
$4,61
—P/E
—
— vs self
Div yield
—
— vs self
ROE
-57,5 %
-77,4 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,64
Predicted surprise
+0,00
Beat probability
45 %
Analysts
9
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-15 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,64 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -43,9M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution9 analysts
Strong buy3
Buy5
Hold1
Sell0
Strong sell0
12-month price target$9,86 · Median $10,00
Low $7,00High $14,00
Operating income · consensus-43,9M USD
EPS surprise
+161,4 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$7,00
Mean$9,86
Median$10,00
High$14,00
Spot$1,70
+479.8 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin17,9 %Above P75
Net Margin31,9 %Above P75
ROE19,9 %Above P75
D/E0,00Above median
Cash Conv1,32Above P75
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 1 550 000 sh5 grants5 insiders
- SEE REMARKS · Stock Option (Right to Buy) → Common StockAcquired 250 000 @ $2,57grant · 2026-01-21
- Director, PRESIDENT & CEO · Stock Option (Right to Buy) → Common StockAcquired 600 000 @ $2,57grant · 2026-01-21
- CHIEF MEDICAL OFFICER · Stock Option (Right to Buy) → Common StockAcquired 250 000 @ $2,57grant · 2026-01-21
- CHIEF SCIENTIFIC OFFICER · Stock Option (Right to Buy) → Common StockAcquired 250 000 @ $2,57grant · 2026-01-21
- SEE REMARKS · Stock Option (Right to Buy) → Common StockAcquired 200 000 @ $2,57grant · 2026-01-21
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
Source documents
- Black Diamond Therapeutics Inc Market data — financials · 2026-05-27
- Black Diamond Therapeutics Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,02 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2024-06-300,00 %$15M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$5M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- David M. EpsteinPresident, Chief Executive Officer, Director
Insider activity
Mixed / flat0 buys · 0 sellsnet $02 insiders · last 365d
- Director · Common StockOther 8 961 @ $1,66$15K · 2026-06-19
- Director · Common StockOther 7 907 @ $1,66$13K · 2026-06-19
- Director · Common StockOther 6 919 @ $2,15$15K · 2026-03-20
- Director · Common StockOther 6 105 @ $2,15$13K · 2026-03-20
- Director · Common StockOther 5 208 @ $2,76$14K · 2025-12-12
- Director · Common StockOther 4 665 @ $2,76$13K · 2025-12-12
- Director · Common StockOther 4 291 @ $3,35$14K · 2025-09-19
- Director · Common StockOther 3 843 @ $3,35$13K · 2025-09-19
Short positioning
5.9Mshares short+30.0% vs prior
3.73days to cover
55.0%short of daily vol
694fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
BDTX.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartners
Evidence & claims
From filings & derived data- Net income (YoY) (2025-12-31 vs 2024-12-31): 132.1%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -21.7%Derived (calculated)
- Return on equity (FY 2025-12-31): 19,933.0%Derived (calculated)
- Return on assets (FY 2025-12-31): 15,640.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 8.42xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.27xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -42.4%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 130.7%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 130.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 147.5%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 115.9%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -34.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 34.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 16.6%Derived (calculated)
- Operating income (annual): USD 12.52MSEC XBRL filing
- Shareholders' equity (annual): USD 112.21MSEC XBRL filing
- Cash & equivalents (annual): USD 20.99MSEC XBRL filing
- Total liabilities (annual): USD 30.8MSEC XBRL filing
- Total assets (annual): USD 143.01MSEC XBRL filing
- R&D expense (annual): USD 33.56MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing
- Current liabilities (annual): USD 15.73MSEC XBRL filing
- Current assets (annual): USD 132.44MSEC XBRL filing
- Operating cash flow (annual): USD 29.61MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-19 00:00 UTCINSIDER2 insider transactions — 2026-06
2026-06-19INSIDERBehbahani Ali transacted 9.0k sh — Director ~$15k
2026-06-19INSIDERRaman Prakash transacted 7.9k sh — Director ~$13k
2026-03-20 00:00 UTCINSIDER2 insider transactions — 2026-03
2026-03-20INSIDERBehbahani Ali transacted 6.9k sh — Director ~$15k
2026-03-20INSIDERRaman Prakash transacted 6.1k sh — Director ~$13k
2026-01-21 00:00 UTCINSIDER5 insider transactions — 2026-01 5 derivative
2026-01-21INSIDERJones Erika acquired 200.0k sh Stock Option (Right to Buy) — SEE REMARKS
2026-01-21INSIDERVelleca Mark A. acquired 600.0k sh Stock Option (Right to Buy) — Director, PRESIDENT & CEO
2026-01-21INSIDERYurasov Sergey acquired 250.0k sh Stock Option (Right to Buy) — CHIEF MEDICAL OFFICER
2026-01-21INSIDERBuck Elizabeth acquired 250.0k sh Stock Option (Right to Buy) — CHIEF SCIENTIFIC OFFICER
2026-01-21INSIDERHatzis-Schoch Brent acquired 250.0k sh Stock Option (Right to Buy) — SEE REMARKS
2025-12-12 00:00 UTCINSIDER2 insider transactions — 2025-12
2025-12-12INSIDERBehbahani Ali transacted 5.2k sh — Director ~$14k
2025-12-12INSIDERRaman Prakash transacted 4.7k sh — Director ~$13k
2025-09-19 00:00 UTCINSIDER2 insider transactions — 2025-09
2025-09-19INSIDERBehbahani Ali transacted 4.3k sh — Director ~$14k
2025-09-19INSIDERRaman Prakash transacted 3.8k sh — Director ~$13k
2025-06-20 00:00 UTCINSIDER8 insider transactions — 2025-06 6 derivative
2025-03-21 00:00 UTCINSIDER9 insider transactions — 2025-03 · net sell $12.0M
2025-01-30 00:00 UTCINSIDER2 insider transactions — 2025-01 1 derivative
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage